The American Diabetes Association published a statement in its journal Diabetes Care advising against the use of compounded GLP-1 RA and dual GIP/GLP-1 RA medications due to concerns about safety, quality and effectiveness. The ADA recommended using only FDA-approved medications for managing type 2 diabetes, weight and other conditions. “Compounded GLP-1 RA and dual GIP/GLP-1 RA products have been associated with clinically important dosing errors and adverse events," the statement said.
Full Story: Medscape (12/3)